Neumedicines Inc. is an emerging therapeutic biotechnology company focused on developing and commercializing innovative and proprietary products and approaches that address unmet clinical and societal needs in the areas of oncology, hematology, and immunology. The company operates from its headquarters in Pasadena, California. Neumedicines' lead product candidate is recombinant human interleukin-12 (rHuIL-12), a heterodimeric glycoprotein and cytokine. rHuIL-12 is being developed under the trade name HemaMax™ for various clinical indications, including hematopoietic syndrome of acute radiation syndrome (HSARS), skin cancers and other solid tumors, and blood disorders and malignancies.